CLL (Chronic lymphocytic leukemia) Plasma / PBMCs (Newly Diagnosed / Untreated)

Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed leukemia in the western world. The diagnosis is established by identification of a clonal B-cell population carrying the CD5 antigen and B-cell markers, resulted from disruption of apoptosis of B cells. CLL progresses slowly and patients often do not feel symptoms for some time, followed by non-painful lymph nodes swelling, feeling tired, fever, or weight loss. Accumulation of small, mature-appearing lymphocytes in the blood, marrow and lymphoid tissues is detected in patients, leading to the diagnosis. Signaling through Ig, mutations, genomic alterations and cell-cell interactions have all been shown to contribute to pathogenesis of CLL.

HumanCells can obtain diseased samples (peripheral blood or bone marrow) when they become available to our network of clinicians. Some disease types may have a long backorder depending on the frequency of the disease occurrence in the general population. All samples come from fully consented IRB approved collections.